87 related articles for article (PubMed ID: 29323872)
1. Glycodendrimer Nanocarriers for Direct Delivery of Fludarabine Triphosphate to Leukemic Cells: Improved Pharmacokinetics and Pharmacodynamics of Fludarabine.
Gorzkiewicz M; Jatczak-Pawlik I; Studzian M; Pułaski Ł; Appelhans D; Voit B; Klajnert-Maculewicz B
Biomacromolecules; 2018 Feb; 19(2):531-543. PubMed ID: 29323872
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine.
Gorzkiewicz M; Deriu MA; Studzian M; Janaszewska A; Grasso G; Pułaski Ł; Appelhans D; Danani A; Klajnert-Maculewicz B
Biomacromolecules; 2019 Mar; 20(3):1429-1442. PubMed ID: 30707833
[TBL] [Abstract][Full Text] [Related]
3. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
4. Cellular and clinical pharmacology of fludarabine.
Gandhi V; Plunkett W
Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
[TBL] [Abstract][Full Text] [Related]
5. Poly(propyleneimine) glycodendrimers non-covalently bind ATP in a pH- and salt-dependent manner - model studies for adenosine analogue drug delivery.
Gorzkiewicz M; Buczkowski A; Appelhans D; Voit B; Pułaski Ł; Pałecz B; Klajnert-Maculewicz B
Int J Pharm; 2018 Jun; 544(1):83-90. PubMed ID: 29653214
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.
Catapano CV; Chandler KB; Fernandes DJ
Cancer Res; 1991 Apr; 51(7):1829-35. PubMed ID: 1706219
[TBL] [Abstract][Full Text] [Related]
7. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and action of fludarabine phosphate.
Plunkett W; Huang P; Gandhi V
Semin Oncol; 1990 Oct; 17(5 Suppl 8):3-17. PubMed ID: 1699280
[TBL] [Abstract][Full Text] [Related]
9. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
Verhoef V; Fridland A
Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
[TBL] [Abstract][Full Text] [Related]
11. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Fraternale A; Rossi L; Magnani M
Biochim Biophys Acta; 1996 Oct; 1291(2):149-54. PubMed ID: 8898876
[TBL] [Abstract][Full Text] [Related]
12. Maltose modified poly(propylene imine) dendrimers as potential carriers of nucleoside analog 5'-triphosphates.
Szulc A; Signorelli M; Schiraldi A; Appelhans D; Voit B; Bryszewska M; Klajnert-Maculewicz B; Fessas D
Int J Pharm; 2015 Nov; 495(2):940-7. PubMed ID: 26456295
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Lichtman SM; Etcubanas E; Budman DR; Eisenberg P; Zervos G; D'Amico P; O'Mara V; Musgrave K; Cascella P; Melikian A; Hinderling PH; Ferrer JM; Williams GJ
Cancer Invest; 2002; 20(7-8):904-13. PubMed ID: 12449721
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.
Pierigè F; De Marco C; Orlotti N; Dominici S; Biagiotti S; Serafini S; Zaffaroni N; Magnani M; Rossi L
Int J Oncol; 2010 Jul; 37(1):133-42. PubMed ID: 20514405
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
17. Effect of the Structure of Therapeutic Adenosine Analogues on Stability and Surface Electrostatic Potential of their Complexes with Poly(propyleneimine) Dendrimers.
Gorzkiewicz M; Appelhans D; Boye S; Lederer A; Voit B; Klajnert-Maculewicz B
Macromol Rapid Commun; 2019 Aug; 40(15):e1900181. PubMed ID: 31136015
[TBL] [Abstract][Full Text] [Related]
18. Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays.
Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Maciejewski H; Voit B; Kaczmarek A; Robak T; Klajnert-Maculewicz B; Cebula-Obrzut B; Smolewski P; Borowiec M; Bryszewska M
Anticancer Agents Med Chem; 2017; 17(1):102-114. PubMed ID: 27349446
[TBL] [Abstract][Full Text] [Related]
19. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ
Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiproliferative potency of 9-beta-D-arabinofuranosyl-2-fluoroadenine phospholipid adducts.
Brachwitz H; Bergmann J; Thomas Y; Wollny T; Langen P
Bioorg Med Chem; 1999 Jun; 7(6):1195-200. PubMed ID: 10428391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
